Full Year 2025 Genscript Biotech Corp Earnings Call Transcript
Key Points
- Genscript Biotech Corp (GNNSF) achieved a 61.4% year-over-year revenue growth, reaching $959.5 million.
- The company's gene to protein platform contributed significantly, accounting for 65% of total revenue growth.
- Genscript's global expansion strategy is effective, with North American and European markets contributing 38% of total revenue.
- The company made significant progress in sustainability, receiving an upgraded ESG rating and inclusion in the FTSE for Good Index Series.
- Legend Biotech, an associate company, achieved profitability in 2025, positively impacting Genscript's financial outlook.
- Genscript Biotech Corp (GNNSF) recorded a loss of $532.4 million due to a shock loss and impairment from its investment in Legend Biotech.
- The gross profit margin for both the Life Science Group and Bestzyme declined compared to 2024.
- Increased SG&A expenses due to global expansion and marketing efforts impacted profitability.
- The company faces intensified market competition and price pressure in the enzyme industry.
- Regulatory scrutiny and geopolitical uncertainties pose potential challenges for the company's operations and customer relations.
Good day and thank you for standing by. Welcome to Jane's Group 2025 annual results conference call. At this time, all participants are a listen-only mode.
After the speaker's presentation, there will be a question-and-answer session.
To ask a question during the session, you need to press star 11 on your telephone.
You will then hear an automated message advising your hand is raised.
To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Mr. Phil Zell, CFO. Please go ahead.
Hello, everyone. This is Phil Zhou, CFO at TranScript.
Welcome to 2025 Annual Results Conference call.
Joining me on the call today are Mr. Robin Meng, Chairman of the board, Ms. Sherryao, rotating CEO of TranScript, Doctor Ray Chen, President of TranScript Life Science Group, Doctor Ai Bai, General Manager of Bedsign.
Mr
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
